BridgeBio data positive for Alnylam and Ionis, says Citi

Citi analyst David Lebowitz says BridgeBio’s (BBIO) positive Phhase III ATTRibute-CM topline data for its TTR stabilizer acoramidis bodes well for Alnylam (ALNY) and Ionis Pharmaceuticals (IONS). Given the evolving severity of the prevalent ATTRCM population post-tafamidis approval, investors had concerns surrounding the implied greater challenges in succeeding versus a control, the analyst tells investors in a research note. The firm says acoramidis showing significant survival benefit compared to placebo should address the fears associated with the risk of population dynamics, “which appeared to have been overdone.”